<font color="blue">Local_2</font> <font color="blue">immunotherapy_2</font> <font color="blue">by_1</font> <font color="blue">inhalation_1</font> <font color="blue">of_1</font> <font color="blue">a_1</font> <font color="blue">powder_1</font> <font color="blue">extract_1</font> in asthma due to <font color="blue">house_1</font> <font color="blue">dust_1</font> <font color="blue">mite_1</font> <font color="blue">Dermatophagoides_1</font> <font color="blue">pteronyssinus_1</font> <font color="blue">:_1</font> a double - blind comparison with <font color="blue">parenteral_1</font> <font color="blue">immunotherapy_1</font> <font color="blue">._1</font> 
<br>
<br> To verify the efficacy and the tolerability of <font color="blue">local_2</font> <font color="blue">immunotherapy_2</font> <font color="blue">(_2</font> <font color="blue">LI_2</font> <font color="blue">)_2</font> <font color="blue">by_2</font> <font color="blue">inhalation_2</font> <font color="blue">of_2</font> <font color="blue">a_2</font> <font color="blue">powder_3</font> <font color="blue">extract_3</font> <font color="blue">of_3</font> <font color="blue">house_3</font> <font color="blue">dust_3</font> <font color="blue">mite_3</font> <font color="blue">(_3</font> <font color="blue">HDM_3</font> <font color="blue">)_3</font> <font color="blue">,_3</font> in comparison with <font color="blue">parenteral_2</font> <font color="blue">immunotherapy_2</font> <font color="blue">(_2</font> <font color="blue">PI_2</font> <font color="blue">)_2</font> <font color="blue">by_1</font> <font color="blue">injection_1</font> <font color="blue">,_1</font> 10 patients with asthma due to HDM were studied in a blind fashion . 5 patients ( Group A ) <font color="blue">underwent_1</font> <font color="blue">LI_2</font> <font color="blue">and_1</font> <font color="blue">subcutaneous_1</font> <font color="blue">injections_1</font> <font color="blue">of_1</font> <font color="blue">placebo_6</font> <font color="blue">,_6</font> <font color="blue">5_2</font> <font color="blue">patients_2</font> <font color="blue">(_2</font> <font color="blue">Group_2</font> <font color="blue">B_2</font> <font color="blue">)_2</font> <font color="blue">underwent_2</font> <font color="blue">PI_3</font> <font color="blue">and_2</font> <font color="blue">inhalation_3</font> <font color="blue">of_3</font> <font color="blue">lactose_6</font> <font color="blue">for_2</font> <font color="blue">6_2</font> <font color="blue">months_2</font> <font color="blue">._2</font> <font color="blue">In_1</font> <font color="blue">both_1</font> <font color="blue">groups_1</font> <font color="blue">each_1</font> <font color="blue">inhalation_1</font> <font color="blue">was_1</font> <font color="blue">preceded_1</font> <font color="blue">by_1</font> <font color="blue">premedication_1</font> <font color="blue">with_1</font> <font color="blue">disodium_5</font> <font color="blue">cromoglycate_5</font> <font color="blue">(_4</font> <font color="blue">DSCG_4</font> <font color="blue">)_4</font> <font color="blue">(_1</font> <font color="blue">40_1</font> <font color="blue">mg_1</font> <font color="blue">)_1</font> <font color="blue">._1</font> In Group A a significant decrease in symptoms score and in peak expiratory flow ( PEF)-derived parameters was observed already after 3 months of treatment , and 2 patients lost the late component of the bronchial response to the challenge with HDM . No significant variation was found in bronchial responsiveness to methacholine and ultrasonically nebulized distilled water ( UNDW ) and in immunologic humoral and cellular parameters in peripheral blood after treatment in either group . No local important adverse reactions were observed in Group A and no systemic side effects were observed in either group . We conclude that <font color="blue">LI_1</font> is as effective as <font color="blue">PI_1</font> <font color="blue">,_1</font> but more rapid in its action , in the treatment of asthma due to HDM . Moreover , <font color="blue">LI_1</font> is locally well tolerated , providing <font color="blue">DSCG_1</font> is inhaled before each <font color="blue">therapeutic_1</font> <font color="blue">inhalation_1</font> <font color="blue">,_1</font> and does not induce systemic side effects .